| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
BEACON [A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)] |
568: Tarcocimab, n=284; 255 treated through week 48 Aflibercept, n=284; 255 treated through week 48 |
Kodiak Sciences NCT04592419 |
Primary completion: June 2022 Study completion: January 2023 |
N/A |
 [Shah.Retina Society.2023]
|